Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 432

1.

Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials.

Murphy BR, Roth M, Kolb EA, Alonzo T, Gerbing R, Wells RJ.

Pediatr Blood Cancer. 2019 Aug;66(8):e27700. doi: 10.1002/pbc.27700. Epub 2019 Mar 25. Review.

PMID:
30908863
2.

Species-specific variations in reproductive traits of three yellow catfish species (Pelteobagrus spp.) in relation to habitats in the Three Gorges Reservoir, China.

Liao C, Chen S, Guo Z, Ye S, Zhang T, Li Z, Murphy BR, Liu J.

PLoS One. 2018 Jul 16;13(7):e0199990. doi: 10.1371/journal.pone.0199990. eCollection 2018.

3.

From Concept to Commerce: Developing a Successful Fungal Endophyte Inoculant for Agricultural Crops.

Murphy BR, Doohan FM, Hodkinson TR.

J Fungi (Basel). 2018 Feb 11;4(1). pii: E24. doi: 10.3390/jof4010024. Review.

4.
5.

Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children.

Karron RA, San Mateo J, Thumar B, Schaap-Nutt A, Buchholz UJ, Schmidt AC, Bartlett EJ, Murphy BR, Collins PL.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e143-6. doi: 10.1093/jpids/piu104. Epub 2014 Nov 12.

6.

One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel.

Simeone JC, Molife C, Marrett E, Frech-Tamas F, Effron MB, Nordstrom BL, Zhu YE, Keller S, Murphy BR, Nair KV, Vetrovec GW, Page RL 2nd, McCollam PL.

Am J Cardiovasc Drugs. 2015 Oct;15(5):337-50. doi: 10.1007/s40256-015-0147-y.

PMID:
26359016
7.

Profundae diversitas: the uncharted genetic diversity in a newly studied group of fungal root endophytes.

Murphy BR, Martin Nieto L, Doohan FM, Hodkinson TR.

Mycology. 2015 Jul 24;6(3-4):139-150. doi: 10.1080/21501203.2015.1070213. eCollection 2015.

8.

Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.

Nordstrom BL, Evans MA, Murphy BR, Nutescu EA, Schein JR, Bookhart BK.

Curr Med Res Opin. 2015 Mar;31(3):439-47. doi: 10.1185/03007995.2014.998814. Epub 2014 Dec 30.

PMID:
25495136
9.

Healthcare providers' perspectives of the supportive care needs of men with advanced prostate cancer.

Carter N, Miller PA, Murphy BR, Payne VJ, Bryant-Lukosius D.

Oncol Nurs Forum. 2014 Jul 1;41(4):421-30. doi: 10.1188/14.ONF.421-430.

PMID:
24969251
10.

Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.

Maximova OA, Speicher JM, Skinner JR, Murphy BR, St Claire MC, Ragland DR, Herbert RL, Pare DR, Moore RM, Pletnev AG.

Vaccine. 2014 May 30;32(26):3187-97. doi: 10.1016/j.vaccine.2014.04.002. Epub 2014 Apr 13.

11.

Rapid life-history diversification of an introduced fish species across a localized thermal gradient.

Zhu F, Rypel AL, Murphy BR, Li Z, Zhang T, Yuan J, Guo Z, Tang J, Liu J.

PLoS One. 2014 Feb 4;9(2):e88033. doi: 10.1371/journal.pone.0088033. eCollection 2014.

12.

Discovery of a new HIV-1 inhibitor scaffold and synthesis of potential prodrugs of indazoles.

Kim SH, Markovitz B, Trovato R, Murphy BR, Austin H, Willardsen AJ, Baichwal V, Morham S, Bajji A.

Bioorg Med Chem Lett. 2013 May 15;23(10):2888-92. doi: 10.1016/j.bmcl.2013.03.075. Epub 2013 Mar 29.

PMID:
23566519
13.

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS.

J Infect Dis. 2013 Mar 15;207(6):957-65. doi: 10.1093/infdis/jis936. Epub 2013 Jan 17.

14.

Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC.

Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14.

15.
16.

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.

Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1267. doi: 10.1371/journal.pntd.0001267. Epub 2011 Aug 2.

17.

The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.

Karron RA, Casey R, Thumar B, Surman S, Murphy BR, Collins PL, Schmidt AC.

Pediatr Infect Dis J. 2011 Oct;30(10):e186-91. doi: 10.1097/INF.0b013e31822ea24f.

18.

The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeys.

Bennett RS, Nelson JT, Gresko AK, Murphy BR, Whitehead SS.

Virol J. 2011 Mar 24;8:136. doi: 10.1186/1743-422X-8-136.

19.

Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys.

Bennett RS, Gresko AK, Murphy BR, Whitehead SS.

Virol J. 2011 Mar 24;8:135. doi: 10.1186/1743-422X-8-135.

20.

Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Schaap-Nutt A, Higgins C, Amaro-Carambot E, Nolan SM, D'Angelo C, Murphy BR, Collins PL, Schmidt AC.

J Virol. 2011 Apr;85(8):4007-19. doi: 10.1128/JVI.02542-10. Epub 2011 Feb 2.

21.

Immune response to dengue virus and prospects for a vaccine.

Murphy BR, Whitehead SS.

Annu Rev Immunol. 2011;29:587-619. doi: 10.1146/annurev-immunol-031210-101315. Review.

PMID:
21219187
22.

Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

Durbin AP, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS.

J Infect Dis. 2011 Feb 1;203(3):327-34. doi: 10.1093/infdis/jiq059. Epub 2010 Dec 14.

23.

Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methylprop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt).

Lockman JW, Murphy BR, Zigar DF, Judd WR, Slattum PM, Gao ZH, Ostanin K, Green J, McKinnon R, Terry-Lorenzo RT, Fleischer TC, Boniface JJ, Shenderovich M, Willardsen JA.

J Med Chem. 2010 Dec 23;53(24):8734-46. doi: 10.1021/jm101145b. Epub 2010 Nov 16.

PMID:
21080724
24.

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.

DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A.

Vaccine. 2010 Dec 10;29(1):17-25. doi: 10.1016/j.vaccine.2010.10.024. Epub 2010 Oct 27.

25.

High-throughput automated image analysis of neuroinflammation and neurodegeneration enables quantitative assessment of virus neurovirulence.

Maximova OA, Murphy BR, Pletnev AG.

Vaccine. 2010 Dec 6;28(52):8315-26. doi: 10.1016/j.vaccine.2010.07.070. Epub 2010 Aug 3.

26.

Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.

Schaap-Nutt A, D'Angelo C, Amaro-Carambot E, Nolan SM, Davis S, Wise SM, Higgins C, Bradley K, Kim O, Mayor R, Skiadopoulos MH, Collins PL, Murphy BR, Schmidt AC.

Virology. 2010 Oct 10;406(1):65-79. doi: 10.1016/j.virol.2010.07.011. Epub 2010 Jul 27.

27.

The effects of feeding history and environment on condition, body composition and growth of bluegills Lepomis macrochirus.

Copeland T, Murphy BR, Ney JJ.

J Fish Biol. 2010 Feb;76(3):538-55. doi: 10.1111/j.1095-8649.2009.02507.x.

PMID:
20666895
28.

Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound.

Fleischer TC, Murphy BR, Flick JS, Terry-Lorenzo RT, Gao ZH, Davis T, McKinnon R, Ostanin K, Willardsen JA, Boniface JJ.

Chem Biol. 2010 Jun 25;17(6):659-64. doi: 10.1016/j.chembiol.2010.05.008.

29.

The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome.

Engel AR, Rumyantsev AA, Maximova OA, Speicher JM, Heiss B, Murphy BR, Pletnev AG.

Virology. 2010 Sep 15;405(1):243-52. doi: 10.1016/j.virol.2010.06.014. Epub 2010 Jul 1.

30.

Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.

Schaap-Nutt A, Scull MA, Schmidt AC, Murphy BR, Pickles RJ.

Vaccine. 2010 Mar 24;28(15):2788-98. doi: 10.1016/j.vaccine.2010.01.050. Epub 2010 Feb 20.

31.

Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.

Bukreyev AA, Dinapoli JM, Yang L, Murphy BR, Collins PL.

Virology. 2010 Apr 10;399(2):290-8. doi: 10.1016/j.virol.2010.01.015. Epub 2010 Feb 2.

32.
33.

Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.

Schaap-Nutt A, D'Angelo C, Scull MA, Amaro-Carambot E, Nishio M, Pickles RJ, Collins PL, Murphy BR, Schmidt AC.

Virology. 2010 Feb 20;397(2):285-98. doi: 10.1016/j.virol.2009.11.018. Epub 2009 Dec 7.

34.

Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, Torres-Velez F, Murphy BR, Samal SK, Collins PL, Bukreyev A.

J Virol. 2010 Feb;84(3):1489-503. doi: 10.1128/JVI.01946-09. Epub 2009 Nov 18.

35.

Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.

Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC.

Am J Trop Med Hyg. 2009 Nov;81(5):834-41. doi: 10.4269/ajtmh.2009.09-0131.

36.

A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.

Bartlett EJ, Cruz AM, Boonyaratanakornkit J, Esker J, Castaño A, Skiadopoulos MH, Collins PL, Murphy BR, Schmidt AC.

Vaccine. 2010 Jan 8;28(3):767-79. doi: 10.1016/j.vaccine.2009.10.069. Epub 2009 Oct 24.

37.

Targeted mutagenesis as a rational approach to dengue virus vaccine development.

Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS.

Curr Top Microbiol Immunol. 2010;338:145-58. doi: 10.1007/978-3-642-02215-9_11. Review.

38.

Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.

Luongo C, Yang L, Winter CC, Spann KM, Murphy BR, Collins PL, Buchholz UJ.

Vaccine. 2009 Sep 18;27(41):5667-76. doi: 10.1016/j.vaccine.2009.07.022. Epub 2009 Jul 29.

39.

Cellular inflammatory response to flaviviruses in the central nervous system of a primate host.

Maximova OA, Faucette LJ, Ward JM, Murphy BR, Pletnev AG.

J Histochem Cytochem. 2009 Oct;57(10):973-89. doi: 10.1369/jhc.2009.954180. Epub 2009 Jul 6.

40.

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

Karron RA, Talaat K, Luke C, Callahan K, Thumar B, Dilorenzo S, McAuliffe J, Schappell E, Suguitan A, Mills K, Chen G, Lamirande E, Coelingh K, Jin H, Murphy BR, Kemble G, Subbarao K.

Vaccine. 2009 Aug 6;27(36):4953-60. doi: 10.1016/j.vaccine.2009.05.099. Epub 2009 Jun 21.

41.

A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.

Talaat KR, Karron RA, Callahan KA, Luke CJ, DiLorenzo SC, Chen GL, Lamirande EW, Jin H, Coelingh KL, Murphy BR, Kemble G, Subbarao K.

Vaccine. 2009 Jun 8;27(28):3744-53. doi: 10.1016/j.vaccine.2009.03.082. Epub 2009 Apr 17.

42.

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K.

J Infect Dis. 2009 Mar 1;199(5):711-6. doi: 10.1086/596558.

43.

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

DiNapoli JM, Ward JM, Cheng L, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A.

Vaccine. 2009 Mar 4;27(10):1530-9. doi: 10.1016/j.vaccine.2009.01.009. Epub 2009 Jan 23.

44.

The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection.

Boonyaratanakornkit JB, Bartlett EJ, Amaro-Carambot E, Collins PL, Murphy BR, Schmidt AC.

J Virol. 2009 Feb;83(4):1892-910. doi: 10.1128/JVI.01373-08. Epub 2008 Dec 3.

45.

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.

Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM, Dorward DW, Pickles RJ, Murphy BR, Feldmann H, Collins PL.

Virology. 2009 Jan 20;383(2):348-61. doi: 10.1016/j.virol.2008.09.030. Epub 2008 Nov 17.

46.

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS.

Am J Trop Med Hyg. 2008 Nov;79(5):678-84.

47.

The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.

Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, Murphy BR, Collins PL.

J Virol. 2008 Dec;82(24):12191-204. doi: 10.1128/JVI.01604-08. Epub 2008 Oct 8.

49.

What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?

Collins PL, Bukreyev A, Murphy BR.

J Virol. 2008 Oct;82(19):9805-6. doi: 10.1128/JVI.01336-08. No abstract available.

50.

Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.

Bartlett EJ, Cruz AM, Esker J, Castaño A, Schomacker H, Surman SR, Hennessey M, Boonyaratanakornkit J, Pickles RJ, Collins PL, Murphy BR, Schmidt AC.

J Virol. 2008 Sep;82(18):8965-77. doi: 10.1128/JVI.00853-08. Epub 2008 Jul 9.

Supplemental Content

Loading ...
Support Center